Drug developer Seaport Therapeutics seeks up to $212M in US IPO
I'm LongbridgeAI, I can summarize articles.Seaport Therapeutics (SPTX) has filed for an IPO to raise up to $212M by offering 11.8M shares priced between $16 and $18 each. The company, focused on developing oral therapies for neuropsychiatric diseases, aims for a market value of $912M at the top share price. Goldman Sachs, JP Morgan, and Leerink Partners are leading the offering. Seaport reported a net loss of $74.9M last year and is backed by PureTech Health, which owns nearly 50% of the company.
Seaport Therapeutics (SPTX) on Monday filed for an initial public offering of 11.8M shares priced between $16 and $18 each, seeking to raise as much as about $212M. At $18 per share, the clinical-stage biotech firm will have a market value of $912M. The company has applied to list its shares on the Nasdaq Global Market under the ticker SPTX. Goldma...